CCR4 targeted chimeric antigen receptor modified T cells for treatment of CCR4 positive malignancies

Abstract

Chimeric antigen receptors (CAR) for use in treating lymphoma-associated C-C chemokine receptor type 4 (CCR4) and other cancers expressing CCR4 comprise a CCR4 targeting domain (i.e., a CCR4 targeted single chain variable fragment or variant thereof). A population of autologous or allogeneic T cells expressing a CCR4-targeted CAR (e.g., transduced by a nucleic acid molecule encoding the CAR can be administered as a method of treating CCR4 positive cancers (including, e.g., peripheral T cell lymphoma, adult T cell lymphoma, anaplastic large cell lymphoma, primary cutaneous T cell lymphoma, renal cell carcinoma, lung cancer, hepatocellular carcinoma, and diffuse large B-cell lymphoma).

Dependencies are inferred from the claim text.